Current status of cytokine-induced killer cells and combination regimens in breast cancer [PDF]
Breast cancer remains a significant health challenge worldwide, with substantial efforts aimed at understanding its pathogenesis, biological characteristics, and clinical triggers.
Yuancong Jiang +3 more
doaj +4 more sources
How can Cytokine-induced killer cells overcome CAR-T cell limits [PDF]
The successful treatment of patients affected by B-cell malignancies with Chimeric Antigen Receptor (CAR)-T cells represented a breakthrough in the field of adoptive cell therapy (ACT).
Elisa Cappuzzello +7 more
doaj +2 more sources
Efficacy of modified dendritic cell–cytokine-induced killer cells loaded with tumour stem cell membrane microparticle therapy in the treatment of relapsed or refractory T- and NK-cell lymphoid proliferations and lymphomas: a report of three cases [PDF]
The prognosis of relapsed or refractory T-cell and NK-cell lymphoid proliferations and lymphomas (R/R T/NK-LPD/LYM) remains poor. Modified dendritic cell–cytokine-induced killer (DC–CIK) cells loaded with tumour stem cell (TSC) membrane microparticles ...
Ao Wang +5 more
doaj +2 more sources
Combined immunotherapy with dendritic cells and cytokine-induced killer cells for solid tumors: a systematic review and meta-analysis of randomized controlled trials [PDF]
Background Immunotherapy utilizing dendritic cells (DCs) and cytokine-induced killer (CIK) cells is a promising treatment approach for solid tumors.
Wendi Jiang +11 more
doaj +2 more sources
Cytokine-induced killer cells mediated pathways in the treatment of colorectal cancer [PDF]
Cytokine-induced killer (CIK) cell therapy is a type of adoptive immunotherapy that due to its high proliferation rate and anti-tumor characteristics, is being investigated to treat various solid tumors.
Farimah Fayyaz +2 more
doaj +2 more sources
Cytokine-induced killer cells: new insights for therapy of hematologic malignancies [PDF]
Background Cytokine-induced killer (CIK) cells are a novel subgroup of immune effectors, classified as one of the modified T cell-mediated arms for immunotherapy.
Faezeh Ghanbari Sevari +4 more
doaj +2 more sources
CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+ rhabdomyosarcoma. [PDF]
Moser LM +16 more
europepmc +2 more sources
Dendritic cells (DCs) are the most potent antigen-presenting cells, and have thus been used in clinical cancer vaccines. However, the effects of DC vaccines are still limited, leading researchers to explore novel ways to make them effective.
Tan-Huy Chu +10 more
doaj +1 more source
Background Rhabdomyosarcoma is the most common soft tissue sarcoma in childhood and has a poor prognosis. Here we assessed the capability of ex vivo expanded cytokine-induced killer cells to lyse both alveolar and embryonic rhabdomyosarcoma cell lines ...
Selim Kuçi +12 more
doaj +1 more source
Background Cytokine-induced killer cells are ex vivo-expanded cells with potent antitumor activity. The infusion of cytokine-induced killer cells in patients with acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplant is ...
Virna Marin +9 more
doaj +1 more source

